首页|耐多药结核病实验室检测技术进展

耐多药结核病实验室检测技术进展

扫码查看
耐多药结核病(MDR-TB)是指对包含异烟肼和利福平同时在内的至少2种以上一线抗结核药物耐药的结核病,其严重威胁着人类的健康和生命,因此早期快速检测耐药情况是MDR-TB患者有效治疗的关键.当前临床MDR-TB诊断主要以表型药物敏感性试验(pDST)检测为主,但pDST检测耗时长,一定程度上延误患者最佳治疗时机,而基因型药物敏感性试验(gDST)则能在较短时间内完成耐药检测.目前在MDR-TB诊断的研究中,pDST检测联合gDST检测是研究热点,但仍处于探索阶段,缺少多中心、大样本、前瞻性研究报道.该文对MDR-TB的实验室检测技术进行综述,以期使读者深入了解MDR-TB的诊断现状及未来研究方向,为MDR-TB的快速诊断及治疗提供参考或借鉴.
Advances in laboratory detection techniques for multidrug-resistant tuberculosis
Multidrug-resistant tuberculosis(MDR-TB)refers to tuberculosis that is resistant to at least two first-line anti-tuberculosis drugs including isoniazid and rifampicin,which seriously threatens human health and life.Therefore,early and rapid detection of drug resistance is the key to effective treatment of MDR-TB patients.At present,the clinical diagnosis of MDR-TB is mainly based on phenotypic drug sensitivity test(pDST),but pDST takes a long time,which delays the best treatment opportunity for patients to some extent,while genotypic drug sensitivity test(gDST)can complete drug resistance detection in a short time.At present,in the research of MDR-TB diagnosis,pDST detection combined with gDST detection is a research hotspot,but it is still in the exploratory stage,lacking of multicenter,large sample and prospective research re-ports.In this paper,the laboratory detection techniques of MDR-TB are reviewed,in order to make readers deeply understand the diagnosis status and future research direction of MDR-TB and provide reference for the rapid diagnosis and treatment of MDR-TB.

tuberculosismultidrug resistancedetectionphenotypic drug sensitivity testgeno-typic drug sensitivity test

刁婷婷、张红吉、欧阳兵、刘超、李晓非

展开 >

云南省昆明市第三人民院/云南省传染性疾病临床医学中心,云南 昆明 650041

大理大学公共卫生学院,云南大理 671003

曲靖医学高等专科学校公共卫生与健康管理学院,云南曲靖 655100

结核病 耐多药 检测 表型药物敏感性试验 基因型药物敏感性试验

2025

检验医学与临床
重庆市卫生信息中心 重庆市临床检验中心

检验医学与临床

影响因子:1.096
ISSN:1672-9455
年,卷(期):2025.22(1)